We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

168 hedge funds and large institutions have $1.24B invested in Arcutis Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

257% more capital invested

Capital invested by funds: $347M → $1.24B (+$892M)

157% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 23

30% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 40

26% more funds holding

Funds holding: 133 → 168 (+35)

5.04% less ownership

Funds ownership: 113.75% → 108.71% (-5%)

42% less call options, than puts

Call options by funds: $6.39M | Put options by funds: $11.1M

Holders
168
Holders Change
+35
Holders Change %
+26.32%
% of All Funds
2.42%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.09%
New
59
Increased
52
Reduced
40
Closed
23
Calls
$6.39M
Puts
$11.1M
Net Calls
-$4.68M
Net Calls Change
-$4.68M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$54.2M
2
GGHC
Gilder Gagnon Howe & Co
New York
+$31.6M
3
Jennison Associates
Jennison Associates
New York
+$23.2M
4
CAM
Cormorant Asset Management
Massachusetts
+$15.9M
5
Citadel Advisors
Citadel Advisors
Florida
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$60.9M
2
Millennium Management
Millennium Management
New York
-$16.3M
3
VPC
Vestal Point Capital
New York
-$8.72M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.07M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$7.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Voloridge Investment Management
26
Voloridge Investment Management
Florida
$9.35M +$7.04M +943,467 New
TC
27
Tejara Capital
United Kingdom
$9.32M -$1.28M -171,730 -15%
Invesco
28
Invesco
Georgia
$8.64M +$6.32M +847,208 +3,370%
Bank of America
29
Bank of America
North Carolina
$8.43M +$5.67M +759,511 +834%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$8.15M +$6.14M +822,461 New
TSC
31
Two Seas Capital
New York
$8.02M +$6.04M +809,332 New
Goldman Sachs
32
Goldman Sachs
New York
$7.99M +$549K +73,522 +10%
Balyasny Asset Management
33
Balyasny Asset Management
Illinois
$7.74M +$5.83M +780,780 New
Charles Schwab
34
Charles Schwab
California
$7.44M +$1.34M +179,406 +31%
PA
35
Perceptive Advisors
New York
$7.43M +$5.6M +750,000 New
Northern Trust
36
Northern Trust
Illinois
$7.42M +$136K +18,201 +2%
Prudential Financial
37
Prudential Financial
New Jersey
$7.17M -$707K -94,730 -12%
Citigroup
38
Citigroup
New York
$7.1M +$5.25M +703,727 +5,535%
SCM
39
Sio Capital Management
New York
$6.3M – – –
IC
40
Ikarian Capital
Texas
$5.84M +$4.4M +589,642 New
HSBC Holdings
41
HSBC Holdings
United Kingdom
$5.01M +$2.7M +362,351 +252%
EC
42
EcoR1 Capital
California
$4.96M +$3.73M +500,000 New
UBS Group
43
UBS Group
Switzerland
$4.86M +$3.65M +488,577 +23,266%
Two Sigma Investments
44
Two Sigma Investments
New York
$4.8M -$3.69M -494,724 -51%
TLP
45
Tri Locum Partners
New York
$4.46M +$3.36M +449,694 New
MIM
46
Monashee Investment Management
Massachusetts
$3.77M +$2.84M +380,000 New
Millennium Management
47
Millennium Management
New York
$3.76M -$16.3M -2,179,829 -85%
TI
48
Trexquant Investment
Connecticut
$3.6M +$2.71M +362,869 New
Federated Hermes
49
Federated Hermes
Pennsylvania
$3.47M -$1.28M -171,355 -33%
AAM
50
AMI Asset Management
California
$3.42M +$2.58M +345,239 New
1
2
3 4 5

ARQT Hedge Fund Activity: Q1 2024 in Review

168 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2024, worth a combined $1.24B — up 257% from $347M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new ARQT positions and 23 closed out — a net gain of 36 holders — while 52 added to existing stakes and 40 trimmed.

The largest buyer was State Street, adding an estimated $54.2M. The largest seller was Morgan Stanley, cutting an estimated $60.9M.

  • 168 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2024, up from 133 in Q4 2023.
  • Funds reported $1.24B of Arcutis Biotherapeutics stock for Q1 2024, up 257% quarter-over-quarter.
  • 59 funds opened new Arcutis Biotherapeutics positions in Q1 2024 and 23 closed out, a net change of +36 holders.
  • The largest Arcutis Biotherapeutics buyer in Q1 2024 was State Street, an estimated $54.2M added.
  • The largest Arcutis Biotherapeutics seller in Q1 2024 was Morgan Stanley, an estimated $60.9M sold.

Based on aggregated 13F filings for Q1 2024.